康柏西普注射液治疗渗出性年龄相关性黄斑变性的临床疗效观察

Observation on clinical efficacy of Kangbai Xipu injection in the treatment of exudative age-related macular degeneration

目的探讨康柏西普注射液治疗渗出性年龄相关性黄斑变性(ARMD)的临床疗效。方法80例渗出性年龄相关性黄斑变性患者,随机分为试验组和对照组,各40例。对照组采取曲安奈德治疗,试验组采取康柏西普注射液治疗。比较两组患者治疗前和治疗后1、2、3个月黄斑中心凹视网膜厚度变化情况。结果治疗前,两组患者黄斑中心凹视网膜厚度比较,差异无统计学意义(P>0.05);试验组治疗后1、2、3个月黄斑中心凹视网膜厚度分别为(278.2±201.0)、(213.0±123.0)、(200.3±123.6)μm,均明显小于对照组的(386.0±200.6)、(296.3±133.6)、(260.6±126.0)μm,差异有统计学意义(P<0.05)。结论渗出性年龄相关性黄斑变性患者采取康柏西普注射液进行治疗,可以改善黄斑中心凹视网膜厚度,值得在临床推广。

Objective To discuss the clinical efficacy of Kangbai Xipu injection in the treatment of exudative age-related macular degeneration (ARMD). Methods A total of 80 patients with exudative agerelated macular degeneration were randomly divided into experimental group and control group, with 40 cases in each group. The control group was treated with triamcinolone acetonide, and the experimental group was treated with Kangbai Xipu injection. The changes of macular fovea retinal thickness before and 1, 2 and 3 months after treatment were compared between the two groups. Results Before treatment, both groups had no statistically significant difference in macular fovea retinal thickness (P>0.05). After 1, 2 and 3 months of treatment, the experimental group had macular fovea retinal thickness respectively as (278.2±201.0),(213.0±123.0) and (200.3±123.6)μm than (386.0±200.6),(296.3±133.6) and (260.6±126.0)μm in the control group, and their difference was statistically significant (P<0.05). Conclusion Kangbai Xipu injection can improve the macular fovea retinal thickness of patients with exudative age-related macular degeneration, and it is worthy of clinical promotion.